You will be shown an abstract from a biomedical research paper. Given this abstract, your task is to extract all unique entities of the following types: ["Outcome", "Participant", "Intervention"].

Please return the output as a JSON object of the format: {"Participant" : ["patients with COPD", ...], "Intervention" : ["Atenolol", ...], "Outcome" : ["blood pressure", ...]}. The keys should be entity types and values should be lists of extracted entities belonging to the corresponding type. If you cannot find entities belonging to a specific type, the value should be [].

Only output the JSON object and do not include any additional text.

Abstract:

Etanercept treatment in adults with established rheumatoid arthritis : 7 years of clinical experience . OBJECTIVE To evaluate safety and efficacy of longterm etanercept treatment in patients with disease modifying antirheumatic drug ( DMARD ) refractory rheumatoid arthritis ( RA ) . METHODS Safety results are reported for 714 patients who received etanercept in one of 7 initial trials or a longterm extension . Efficacy results are reported for 581 patients who enrolled in the extension . RESULTS Of the 714 patients enrolled in the initial trials , 581 ( 81 % ) enrolled in the extension , and 388 ( 54 % ) patients are continuing to receive etanercept therapy . The longest individual treatment was 8.2 years , with 3139 total patient-years of etanercept exposure . Rates of serious adverse events ( overall rate=14.8 events/100 patient-yrs ) , serious infections ( overall rate=4.2 events/100 patient-yrs ) , cancer ( overall rate=1.0 events/100 patient-yrs ) , and deaths ( overall rate=0.7 events/100 patient-yrs ) were stable each year , through 8 years of etanercept exposure . For 356 patients who completed 6 years of etanercept treatment , response rates were ACR20=73 % , ACR50=52 % , ACR70=27 % , DAS28 CRP good response=52 % , and DAS28 CRP remission=37 % of patients . Similar responses occurred in 167 patients who completed Year 7 . Doses of concomitant methotrexate or corticosteroids were reduced in many patients who maintained clinical responses . CONCLUSION The safety profile of etanercept was consistent over time , with rates of adverse events similar to those reported for patients with RA in general . Durable clinical responses were observed in some patients for 7 years or more . The benefit-to-risk ratio for longterm etanercept treatment remains highly favorable .
{"Intervention": ["Etanercept", "etanercept"], "Outcome": ["Rates of serious adverse events", "serious infections", "safety profile", "efficacy", "cancer", "deaths", "rates of adverse events", "Doses", "response rates", "safety"], "Participant": ["rheumatoid arthritis :", "388", "disease modifying antirheumatic drug ( DMARD ) refractory rheumatoid arthritis ( RA )", "167", "356", "714", "581", "RA", "adults"]}